Jove
Visualize
Contact Us

Related Experiment Videos

Drug-induced systemic lupus erythematosus.

M A Stratton

    Clinical Pharmacy
    |November 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Drug-induced systemic lupus erythematosus (SLE), often caused by hydralazine or procainamide, shares similarities with idiopathic SLE but typically presents with fewer severe organ involvements. Monitoring patients on these drugs for SLE symptoms is crucial.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Pharmacodynamic considerations in the elderly.

    Experimental lung research·2006
    Same author

    Prevention of venous thromboembolism: adherence to the 1995 American College of Chest Physicians consensus guidelines for surgical patients.

    Archives of internal medicine·2000
    Same author

    Chronic obstructive pulmonary disease.

    Primary care·1990
    Same author

    Using an interdisciplinary team for geriatric education in a nursing home.

    Journal of medical education·1988
    Same author

    Short-course drug therapy for tuberculosis.

    Clinical pharmacy·1986
    Same author

    Hypersensitivity vasculitis associated with streptokinase.

    Clinical pharmacy·1985
    Same journal

    Criteria for use of epoetin alfa in adult cancer and orthopedic-surgery patients.

    Clinical pharmacy·1993
    Same journal

    Accuracy of unbound-quinidine concentration determination after ultrafiltration.

    Clinical pharmacy·1993
    Same journal

    Modified Michaelis-Menten equation for estimating unbound-phenytoin concentrations.

    Clinical pharmacy·1993
    Same journal

    Predicting vancomycin pharmacokinetics by using aminoglycoside pharmacokinetics.

    Clinical pharmacy·1993
    Same journal

    Efficacy of nutritional supplements used by athletes.

    Clinical pharmacy·1993
    Same journal

    Low-molecular-weight heparins for the treatment of deep-vein thrombosis.

    Clinical pharmacy·1993
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies

    Area of Science:

    • Rheumatology
    • Clinical Pharmacology
    • Immunology

    Background:

    • Systemic lupus erythematosus (SLE) can be triggered by certain medications, with hydralazine and procainamide being primary culprits.
    • The exact cause of SLE remains unknown, though genetic factors play a significant role.
    • Over 25 drugs have been implicated, but hydralazine and procainamide account for most confirmed drug-induced SLE cases.

    Purpose of the Study:

    • To review and compare drug-induced SLE with idiopathic SLE.
    • To discuss the implications of using hydralazine and procainamide in patients with idiopathic SLE.
    • To highlight key differences and similarities in clinical and laboratory manifestations.

    Main Methods:

    • Literature review and comparative analysis of drug-induced SLE versus idiopathic SLE.

    Related Experiment Videos

  • Examination of etiological factors, focusing on hydralazine and procainamide.
  • Analysis of clinical presentations, demographic data, and laboratory findings.

    • Main Results:

    • Drug-induced SLE, particularly from hydralazine and procainamide, often presents with musculoskeletal symptoms like arthritis.
    • Patients with drug-induced SLE are generally older and have a higher male-to-female ratio compared to idiopathic SLE.
    • While clinical and lab findings overlap, central nervous system and renal involvement are less common in drug-induced SLE.

    Conclusions:

    • Hydralazine and procainamide can induce SLE by interacting with nucleoproteins and stimulating antinuclear antibody (ANA) production.
    • Baseline ANA testing and careful patient monitoring are recommended before and during therapy with these drugs.
    • Limited daily doses of hydralazine (≤200 mg) may mitigate risk, and alternative treatments should be considered for patients with idiopathic SLE who may experience exacerbations from certain drugs.